Ohio State University
osu.eduTotal trials
980
Active
282
Phase 3
12
Total enrollment
23,756,535
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 86 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nicotine Oral Pouch | — | — | 6 | ||||
| Insulin | — | — | — | — | — | 2 | |
| Atropine Ophthalmic | — | — | — | — | 2 | ||
| Atorvastatin 10 mg | — | — | — | — | — | 1 | |
| Bactrim or Macrobid | — | — | — | — | — | 1 | |
| Sacubitril-Valsartan Tab 97-103 MG | — | — | — | — | — | 1 | |
| Valsartan 160mg | — | — | — | — | — | 1 | |
| Pancrelipase | — | — | — | — | — | 1 | |
| BCG Solution | — | — | — | — | — | 1 | |
| Ceftriaxone 1000 MG | — | — | — | — | — | 1 | |
| Clarithromycin 500mg | — | — | — | — | — | 1 | |
| Metronidazole 500 mg | — | — | — | — | — | 1 | |
| Ampicillin 2 GM | — | — | — | — | — | 1 | |
| Amoxicillin 250 MG | — | — | — | — | — | 1 | |
| Azithromycin | — | — | — | — | — | 1 | |
| Erythromycin | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 1 | |
| Alloderm | — | — | — | — | — | 1 | |
| MicroDerm | — | — | — | — | — | 1 | |
| Aspirin 81 mg | — | — | — | — | — | 1 | |
| Aspirin 162 mg | — | — | — | — | — | 1 | |
| Reduced Nicotine Content Cigars | — | — | — | — | — | 1 | |
| Normal nicotine content cigar | — | — | — | — | — | 1 | |
| Usual brand cigar | — | — | — | — | — | 1 | |
| antibiotic prophylaxis | — | — | — | — | — | 1 | |
| Atropine Sulfate 0.05% Oph Soln | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | 11 | ||||
| Carboplatin | — | — | — | 7 | |||
| cisplatin | — | — | — | 8 | |||
| Venetoclax | — | — | — | — | — | 3 | |
| Ibrutinib | — | — | — | — | 3 | ||
| Minoxidil | — | — | — | — | 2 | ||
| Cigarette | — | — | — | — | 2 | ||
| Smokeless Tobacco | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | 2 | ||
| Liposome-encapsulated Daunorubicin-Cytarabine | — | — | — | — | — | 2 | |
| Leuprolide | — | — | — | — | — | 1 | |
| Relugolix | — | — | — | — | — | 1 | |
| Acalabrutinib | — | — | — | — | — | 1 | |
| Obinutuzumab | — | — | — | — | — | 1 |
46 more active programs hidden
Next readouts
- 2024-02-08
- 2025-03-17
- 2025-08-31
- 2025-12-30
- 2025-12-31
- 2026-06-02
- 2026-06-30
- 2026-07-31
- 2026-08
- 2026-08-15
Top conditions
- Breast Cancer27
- Obesity18
- Anatomic Stage II Breast Cancer AJCC v816
- Depression16
- Anatomic Stage III Breast Cancer AJCC v815
- Anxiety15
- Malignant Solid Neoplasm14
- Tobacco-Related Carcinoma14
Frequently asked questions about Ohio State University
- How many clinical trials does Ohio State University have on ClinicalTrials.gov?
- Ohio State University is listed as the lead sponsor on 980 clinical trials in ClinicalTrials.gov, 282 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ohio State University's trials are in Phase 3?
- 12 of Ohio State University's trials are in Phase 3, spread across 86 active drug programs.
- What therapeutic areas does Ohio State University focus on?
- Ohio State University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Anatomic Stage II Breast Cancer AJCC v8, Depression, Anatomic Stage III Breast Cancer AJCC v8.
- When are Ohio State University's next clinical trial readouts?
- Ohio State University has 10 upcoming primary-completion readouts tracked here; the soonest is “The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans”, expected around 2024-02-08.